These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36899615)

  • 1. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
    Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
    Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endoplasmic reticulum stress related IncRNA signature predicts the prognosis and immune response evaluation of uterine corpus endometrial carcinoma.
    Chen J; Shen L; Yang Y
    Front Oncol; 2022; 12():1064223. PubMed ID: 36686816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of methylation-driven genes prognosis signature and immune microenvironment in uterus corpus endometrial cancer.
    Liu J; Ji C; Wang Y; Zhang C; Zhu H
    Cancer Cell Int; 2021 Jul; 21(1):365. PubMed ID: 34246261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
    Sun XX; Wen HQ; Zhan BX; Yang P
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma.
    Wei S; Zhang J; Shi R; Yu Z; Chen X; Wang H
    Front Oncol; 2022; 12():944000. PubMed ID: 36158685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
    Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
    Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
    Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
    Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
    Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
    Front Oncol; 2022; 12():923641. PubMed ID: 35719911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
    Miao C; Fang X; Chen Y; Zhao Y; Guo Q
    Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. m
    Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
    BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
    Wang Y; Ren F; Song Z; Wang X; Ma X
    J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
    Liu W; Sun L; Zhang J; Song W; Li M; Wang H
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a 4-miRNA prognostic signature for endometrial cancer.
    Huang J; Du F; Wang N
    Medicine (Baltimore); 2022 Oct; 101(41):e30974. PubMed ID: 36254064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma.
    Zhou C; Li C; Yan F; Zheng Y
    Cancer Cell Int; 2020 Nov; 20(1):541. PubMed ID: 33292199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.